Comments
Actavis forecasts 2012 sales in excess of 2 billion euros
19.10.2012. | FRANKFURT (Reuters) - Actavis, the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than 2 billion euros ($2.6 billion) this year, driven by patent expiries in Europe and strong demand in the United States....
